1-3 of 3
Daniel J. De Angelo
Close
Sort by
Journal Articles

A Randomized Comparison of Induction Therapy for Untreated Acute Myeloid Leukemia (AML) in Patients < 60 Years Using P-Glycoprotein (Pgp) Modulation with Valspodar (PSC833): Preliminary Results of Cancer and Leukemia Group B Study 19808.

Jonathan E. Kolitz, Stephen L. George, Guido Marcucci, Ravi Vij, Bayard L. Powell, Steven L. Allen, Daniel J. De Angelo, Thomas Shea, Wendy Stock, Vera Hars, Eva Hoke, James W. Vardiman, Clara D. Bloomfield, Richard A. Larson
Journal: Blood
Blood (2005) 106 (11): 407.
https://doi.org/10.1182/blood.V106.11.407.407
Published: 2005
Journal Articles

Addition of Bortezomib (Velcade) to AML Induction Chemotherapy Is Well Tolerated and Results in a High Complete Remission Rate.

Eyal C. Attar, MD, Daniel J. De Angelo, MD, PhD, Andres Sirulnik, MD, PhD, Martha Wadleigh, MD, Karen K. Ballen, MD, Kenneth B. Miller, MD, Ilene Galinsky, Donna Neuberg, PhD, Elizabeth Trehu, MD, David Schenkein, MD, Richard M. Stone, MD, Philip C. Amrein, MD
Journal: Blood
Blood (2005) 106 (11): 2782.
https://doi.org/10.1182/blood.V106.11.2782.2782
Published: 2005
Journal Articles

Phase II Evaluation of the Tyrosine Kinase Inhibitor MLN518 in Patients with Acute Myeloid Leukemia (AML) Bearing a FLT3 Internal Tandem Duplication (ITD) Mutation.

Daniel J. De Angelo, MD,PhD, Richard M. Stone, MD, Mark L. Heaney, MD,PhD, Stephen D. Nimer, MD, Ronald Paquette, MD, Rebecca Bruner-Klisovic, MD, Michael A. Caligiuri, MD, Michael R. Cooper, MD, Jean-Michel LeCerf, PhD, Ganesh Iyer, PhD, Michael C. Heinrich, MD, Brian J. Druker, MD
Journal: Blood
Blood (2004) 104 (11): 1792.
https://doi.org/10.1182/blood.V104.11.1792.1792
Published: 2004